Skip to content

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

  1. Home/
  2. News/
  3. Innovation/
  4. Innovation-opedia: What is a mosaic vaccine?
Graphic featuring a syringe to illustrate an HIV vaccine trial

Innovation-opedia: What is a mosaic vaccine?

As the IAS Conference on HIV Science kicks off in Mexico City, we explain how an investigational HIV vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson works—and how researchers hope to help change lives around the world with it.

Illustrated handwritten definition of a mosaic HIV vaccine
Illustration of a microscope with information about Janssen Vaccines & Prevention B.V. investigational HIV-1 vaccine regimen
Inset- Innovation-opedia: What Is a Mosaic Vaccine?- mosaic-vaccine-4-immunizations_above
Illustration of the # 4 explaining how many injections would be administered for Janssen’s investigational HIV-1 vaccine.
Inset- Innovation-opedia: What Is a Mosaic Vaccine?- mosaic-vaccine-4-immunizations_below
Illustration showing location of the IAS Conference on HIV Science with details about Janssen’s new Mosaico clinical trial.
Illustrated quote by Janssen’s Maria Grazia Pau talking about the goal of creating a global HIV vaccine.

We’re committed to helping lead the fight against HIV/AIDS

Read about the many ways Johnson & Johnson is working to #makeHIVhistory.

More from Johnson & Johnson

6 ways Johnson & Johnson is using AI to help advance healthcare

Artificial intelligence is revolutionizing healthcare—from improving surgical training and procedures to equipping healthcare providers with insights and personalizing care for patients around the world. See how the company is harnessing its extraordinary power.

How Johnson & Johnson is advancing the fight against Alzheimer’s disease

After decades of commitment to understanding this neurodegenerative disease, company scientists have developed innovative therapies and tools that can potentially slow its progression and ease the psychological toll on patients and caretakers. A cure is still elusive—but preventing the disease may be within reach.

Is this the end of one-size-fits-all treatments for depression?

Learn how Johnson & Johnson is working to better address the needs of the 7 in 10 people with depression whose treatments aren’t providing enough relief.